<DOC>
	<DOC>NCT01737944</DOC>
	<brief_summary>Pharmacokinetics (PK) study</brief_summary>
	<brief_title>Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration</brief_title>
	<detailed_description>To compare the pharmacokinetic (PK) profiles of methotrexate (MTX) following a subcutaneous (SC) injection of MTX using the Vibex device to that obtained after an SC injection of MTX without using the device and to that obtained after an intramuscular (IM) injection of MTX in adult subjects with rheumatoid arthritis (RA).</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Male or female &gt;18 years of age with diagnosed Rheumatoid Arthritis(RA). Chronic or acute renal disease Any other clinically significant disease or disorder which, in the opinion of the investigator, might put the subject at risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>methotrexate injection, subcutaneous, autoinjector</keyword>
</DOC>